What Happened?
South San Francisco, CA-based Tscan Appointed David Southwell as Chief Executive Officer
About the Company
Tscan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About the Person
David Southwell is Chief Executive Officer at Tscan. Previously, David held various senior HR leadership roles in the industry.
Info Source
News
Short Profile